GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes four assets under development. Other assets target other life-threatening disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA).
Join key BioFIT 2025 sponsors such as GENFIT to take advantage of the following opportunities:
- Identify your organisation with the main partnering event in Europe dedicated to technology transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
- Highlight your interest in early-stage innovation
- Present your ideas and technologies to key innovation players in Life Sciences
- Enhance your visibility on an international scale and be recognised as a key innovative player
- Demonstrate your expertise using specific communication tools
For more information about the sponsorship opportunities, visit the dedicated site page
